Takeda shares suffer despite claims of solid quarter

30 July 2021

Japanese drugmaker Takeda (TYO: 4502) closed 2% down after Tokyo’s trading day on Friday, having presented its financial results from the first quarter, under Japan’s April 2021 to March 2022 financial year.

Takeda described the results as ‘solid’. They showed an 18% rise in revenue to 949.6 billion yen ($8.66 billion) which translates to underlying growth of 4% and topped analysts’ expectations.

"The potential for five approvals by end of the first half of financial year 2022"The firm also grew reported operating profit by 49% to 248.6 billion yen, albeit that the underlying comparison, when adjustments are taken into account, showed a 2% decline.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK